Brief: Pyxis Oncology Announces Initiatives To Prioritize Lead Adc Program Reports Financial Results For Third-Quarter 2023 And Provides Corporate Update

Pyxis Oncology

07/11/2023 22:22

Nov 7 (Reuters) - Pyxis Oncology Inc  PYXS.O :
    * PYXIS ONCOLOGY ANNOUNCES INITIATIVES TO PRIORITIZE LEAD
ADC
PROGRAM; REPORTS FINANCIAL RESULTS FOR THIRD-QUARTER 2023 AND
PROVIDES CORPORATE UPDATE
    * PYXIS ONCOLOGY INC - PYX-201  PHASE 1 TRIAL PROGRESSING
WITH
FIFTH DOSE COHORT AT 3.6 MG/KG; DATA EXPECTED 1H 2024
    * PYXIS ONCOLOGY INC -  PYX-106 PHASE 1 TRIAL NOW FOCUSING
ON
NSCLC AND OTHER TUMOR TYPES; DATA EXPECTED 2H 2024
    * PYXIS ONCOLOGY INC - CASH RUNWAY EXTENDED TO EARLY 2026
DUE TO
COST REDUCTIONS AND PORTFOLIO PRIORITIZATION
    * PYXIS ONCOLOGY INC - ENDED Q3 OF 2023 WITH ABOUT $134.4
MILLION
IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND SHORT-TERM
INVESTMENTS
    * PYXIS ONCOLOGY INC - COST REDUCTIONS ANNOUNCED TODAY 
INCLUDE A
40% DECREASE IN HEADCOUNT
    * PYXIS ONCOLOGY INC - ALSO SEEKING ADDITIONAL NON-DILUTIVE
FUNDING THROUGH POTENTIAL MONETIZATION OF OUR ACQUIRED APEXIGEN
ROYALTY STREAMS
    * PYXIS ONCOLOGY INC - PAUSING FUNDING OF CERTAIN
EARLY-STAGE
RESEARCH PROGRAMS
    * PYXIS ONCOLOGY INC - QTRLY LOSS PER SHARE $0.56

Source text for Eikon:  ID:nGNX1KH4XN 
Further company coverage:  PYXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))